Anzeige
Mehr »
Login
Mittwoch, 24.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News: InnoCan startet in eine neue Ära – FDA Zulassung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EEZB | ISIN: US72941H5090 | Ticker-Symbol: XMP0
Tradegate
22.04.24
15:15 Uhr
1,592 Euro
+0,046
+2,98 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PLUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PLUS THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,4901,55023.04.
1,4941,60023.04.

Aktuelle News zur PLUS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoMicro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense3
09.04.Plus Therapeutics Inc.: Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus' Management Team120The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will maintain his academic commitments but will greatly contribute to Plus' scientific...
► Artikel lesen
14.03.Plus Therapeutics faces Nasdaq delisting over equity shortfall9
13.03.PLUS THERAPEUTICS, INC. - 8-K, Current Report3
08.03.PLUS THERAPEUTICS, INC. - S-1/A, General form for registration of securities4
07.03.Plus Therapeutics, Inc. (PSTV) Q4 2023 Earnings Call Transcript5
06.03.Earnings call: Plus Therapeutics shows progress in CNS cancer trials3
06.03.Plus Therapeutics Inc reports results for the quarter ended in December - Earnings Summary3
05.03.Recap: Plus Therapeutics Q4 Earnings3
05.03.Plus Therapeutics GAAP EPS of -$4.24 misses by $3.073
05.03.Plus Therapeutics Inc.: Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights355Began enrollment of the 5th of an anticipated 7 planned dosing cohorts for the ReSPECT-LM Phase 1 dose escalation trial with rhenium (186Re) obisbemeda for leptomeningeal metastases (LM) Reached agreement...
► Artikel lesen
05.03.PLUS THERAPEUTICS, INC. - 8-K, Current Report1
05.03.PLUS THERAPEUTICS, INC. - 10-K, Annual Report2
04.03.Plus Therapeutics Earnings Preview4
18.12.23Plus Therapeutics Inc.: Plus Updates Financial and Cash Guidance for 2024427Plus Receives $3.3M in grant revenue in Q4 2023 Forecasts additional $6.9M of grant revenue for 2024 Enters into debt restructuring deal with Pershing Capital to reduce 2024 cash burn by $3.7M AUSTIN...
► Artikel lesen
22.11.23Plus Therapeutics files to sell ordinary shares, warrants10
22.11.23PLUS THERAPEUTICS, INC. - S-1, General form for registration of securities2
20.11.23Fortress Biotech, Plus Therapeutics among healthcare movers11
20.11.23Plus Therapeutics Announces Positive Results From ReSPECT-GBM Phase 2 Study473WASHINGTON (dpa-AFX) - Clinical-stage pharmaceutical company Plus Therapeutics, Inc. (PSTV) Monday announced initial positive data from the ReSPECT-GBM Phase 2 study of its lead radiotherapeutic...
► Artikel lesen
20.11.23PLUS THERAPEUTICS, INC. - 8-K, Current Report4
Seite:  Weiter >>
46 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1